Invokana Bellwether Personal Injury Trial: Johnson and Johnson

The first bellwether trial for Invokana (canagliflozin) has been scheduled to begin September 2018, per a Case Management Order signed by the Court on May 1, 2017.  Currently, over 230 Invokana and Invokamet personal injury lawsuits have been filed alleging Johnson & Johnson withheld critical information about the drugs’ link to ketoacidosis and other life threatening side effects.

In a bellwether trial, test cases are selected from the filed complaints to go before a jury in order to gauge responses to the issue.  As it is not practical to bring every case to trial, these results will help shape the process in dealing with the remaining cases and ascertain value.

The discovery process is to take place between September 1, 2017 and December 15, 2017 with four case-specific depositions permitted per side.  Recommendations for the bellwether trial pool are due by January 5, 2018, with the Court making final decisions of three bellwether cases for trial and order by January 19th.

The cases have been consolidated in New Jersey as part of a federal multidistrict litigation before U.S. District Judge Brian Martinotti.

It is expected that thousands of claims will ultimately be filed as attorneys continue to receive consumer complaints and file claims across the United States.

Read the entire order, here.